The Cure Starts Now follows an extensive grant approval process to ensure your dollars make the biggest impact to homerun cancer research. Take comfort in knowing that The Cure Starts Now only funds: research that follows our mission, research that is non-duplicative, and research that is financially sound.


The Cure Starts Now has funded $23,988,300 (USD) in pediatric brain cancer research in partnership with the DIPG / DMG Collaborative. This includes 154 grants at over 100 hospitals in 29 countries.




University Hospital of Navarra - $100,000 USD, €92,637 EUR

Amount
$100,000.00
Date
October 2024

Targeting Diffuse Midline Glioma vulnerabilities as a therapeutic strategy.

The Institute of Cancer Research – $111,445 USD / £85,976 GBP

Amount
$111,445.00
Date
October 2024

Unravelling transcriptional plasticity as a non-genetic mechanism of drug resistance in DMG.

McGill University - $100,000

Amount
$100,000.00
Date
October 2024

Understanding tumor heterogeneity and characterizing treatment responses in ACVR1-mutated diffuse midline gliomas.

Cincinnati Children’s Hospital Medical Center - $200,000

Amount
$200,000.00
Date
October 2024

Combining FLASH and immunotherapy to target medulloblastoma relapse

Emory University / Cincinnati Children's Hospital – $93,250

Amount
$93,250.00
Date
March 2024

SUMOylation as a novel therapeutic target in DIPG

University of Chicago Medical Center / Washington University St. Louis – $100,000

Amount
$100,000.00
Date
December 2023

Characterizing and Targeting ABL1 and ABL2 in Medulloblastoma Leptomeningeal Dissemination.

Icahn School of Medicine at Mount Sinai – $100,000

Amount
$100,000.00
Date
December 2023

Targeting macrophages to improve the survival of DIPG

Children’s Cancer Institute – $50,000

Amount
$50,000.00
Date
December 2023

A novel formulation to allow the simultaneous targeting of MYCN expression and copper chelation to treat DIPG tumour and overcome multidrug resistance.

Children’s Hospital Colorado – $100,000

Amount
$100,000.00
Date
December 2023

Dual targeting processive transcription for Myc-driven circuitry in medulloblastoma.

University of Newcastle – $116,997 USD, 173,016 AUD

Amount
$116,997.00
Date
December 2023

(2023) Enhancing the recruitment of tumor infiltrating lymphocytes to improve responses to DMG therapies.

Princess Máxima Center for Pediatric Oncology – $98,306

Amount
$98,306.00
Date
December 2023

Assessing the potential of the HDAC inhibitor givinostat ± radiotherapy for the treatment of diffuse midline glioma.

Nemours Children’s Hospital - $50,000

Amount
$50,000.00
Date
December 2023

Treatment of Diffuse Intrinsic Pontine Glioma with the Oncolytic Zika Virus.

Icahn School of Medicine at Mount Sinai - $100,000

Amount
$100,000.00
Date
December 2023

Preclinical evaluation of TP-0184 in an autochthonous mouse model of DIPG/DMG

The University of Alabama at Birmingham – $100,000

Amount
$100,000.00
Date
December 2023

Intranasal Delivery of Targeting Nanotherapeutics for DIPG

Funding of PBTCF 2023 - $25,000

Amount
$25,000.00
Date
December 2023